Posted by on March 24, 2018 7:18 am
Categories: Crispr

Apple Makes Another Big Splash in Healthcare – Sangamo Stock’s Cancer Opportunity

Two huge healthcare stories: Apple pushes further into healthcare, and little-known small-cap Sangamo Therapeutics gets a huge cash infusion.

Sangamo stock’s zinc finger technology is exciting because of its potential for gene editing — if the data continues to be good, it could make a big difference in hemophilia, cancer, and a variety of other diseases. In fact, Sangamo’s technology has such a big opportunity in cancer that Gilead Sciences paid up to license it.

In another major story, Apple has opened new wellness centers with the aim of boosting care (and reducing healthcare costs) for its employees. Taken in combination with Apple’s HealthKit, this could represent the beginning of a major move into healthcare…with huge implications for the company’s profitability.

Comment below to let us know what you thought or to ask questions!

This video was filmed on February 28th, 2018.

You can read more about The Motley Fool’s disclosure policy here:
Subscribe to The Motley Fool’s YouTube Channel:
Join our Facebook community:
Follow The Motley Fool on Twitter:

Or, follow our Google+ page:

Inside The Motley Fool: Check out our Culture Blog!

Leave a Reply